Abstract:FTO elevation in Epstein‒Barr virus‐associated GC contributes to favourable prognosis in patients. FTO restrains tumour metastasis and aggressiveness in EBVaGC by down‐regulating FOS in an m6A‐dependent manner. The m6A readers IGF2BP1/2 bind FOS nascent transcripts and maintain FOS mRNA stability. Targeting the FTO⊣FOS/ IGF2BP1/2 axis renders a promising strategy for GC therapy. Background Epstein‒Barr virus‐associated gastric cancer (EBVaGC) is regarded as a distinct molecular subtype of GC, accounting for approximately 9% of all GC cases. Clinically, EBVaGC patients are found to have a significantly lower frequency of lymph node metastasis and better prognosis than uninfected individuals. RNA N6‐methyladenosine (m6A) modification has an indispensable role in modulating tumour progression in various cancer types. However, its impact on EBVaGC remains unclear. Methods Methylated RNA immunoprecipitation sequencing (MeRIP‐seq) and m6A dot blot were conducted to compare the m6A modification levels between EBVaGC and EBV‐negative GC (EBVnGC) cells. Western blot, real‐time quantitative PCR (RT‐qPCR) and immunohistochemistry were applied to explore the underlying mechanism of the reduced m6A modification in EBVaGC. The biological function of fat mass and obesity‐associated protein (FTO) was determined in vivo and in vitro. The target genes of FTO were screened by MeRIP‐seq, RT‐qPCR and Western blot. The m6A binding proteins of target genes were verified by RNA pulldown and RNA immunoprecipitation assays. Chromatin immunoprecipitation and Luciferase report assays were performed to investigate the mechanism how EBV up‐regulated FTO expression. Results M6A demethylase FTO was notably increased in EBVaGC, leading to a reduction in m6A modification, and higher FTO expression was associated with better clinical outcomes. Furthermore, FTO depressed EBVaGC cell metastasis and aggressiveness by reducing the expression of target gene AP‐1 transcription factor subunit (FOS). Methylated FOS mRNA was specifically recognized by the m6A 'reader' insulin‐like growth factor 2 mRNA binding protein 1/2 (IGF2BP1/2), which enhanced its transcripts stability. Moreover, MYC activated by EBV in EBVaGC elevated FTO expression by binding to a specific region of the FTO promoter. Conclusions Mechanistically, our work uncovered a crucial suppressive role of FTO in EBVaGC metastasis and invasiveness via an m6A‐FOS‐IGF2BP1/2‐dependent manner, suggesting a promising biomarker panel for GC metastatic prediction and therapy.

WNT/β-catenin-suppressed FTO expression increases m 6 A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

WNT/β-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

WNT/-catenin-suppressed FTO expression increases m<SUP>6</SUP>A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer

Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

N 6 -methyladenosine demethyltransferase FTO mediated m 6 A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis

N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m6A modification of caveolin-1 and metabolic regulation of mitochondrial dynamics

FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m 6 A modifications of multiple pro-angiogenic factors

N6-methyladenosine Demethyltransferase FTO Mediated M6a Modification of Estrogen Receptor Alpha in Non-Small Cell Lung Cancer Tumorigenesis

FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner

N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1 alpha signalling axis

FTO Promotes Clear Cell Renal Cell Carcinoma Progression Via Upregulation of PDK1 Through an M6a Dependent Pathway

Effect of demethyltransferase FTO on tumor progression

FTO promotes the progression of bladder cancer via demethylating m6A modifications in PTPN6 mRNA

FTO Elicits Tumor Neovascularization in Cancer-Associated Fibroblasts Through Eliminating M6a Modifications of Multiple Pro-Angiogenic Factors

Fat mass and obesity-associated protein (FTO) mediated m6A modification of circFAM192A promoted gastric cancer proliferation by suppressing SLC7A5 decay

FTO up‐regulation induced by MYC suppresses tumour progression in Epstein‒Barr virus‐associated gastric cancer

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade